Compare PPTA & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPTA | ICUI |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.0B |
| IPO Year | 2011 | 1995 |
| Metric | PPTA | ICUI |
|---|---|---|
| Price | $27.70 | $118.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $37.38 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 1.1M | 220.5K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.46 |
| P/E Ratio | ★ N/A | $3,961.17 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.68 | $107.02 |
| 52 Week High | $37.37 | $160.29 |
| Indicator | PPTA | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 38.42 |
| Support Level | $26.03 | $114.51 |
| Resistance Level | $30.77 | $133.16 |
| Average True Range (ATR) | 1.44 | 4.31 |
| MACD | -0.44 | -0.55 |
| Stochastic Oscillator | 19.32 | 29.60 |
Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.